Chelsea Therapeutics International Ltd., of Charlotte, N.C., said an independent data safety monitoring board recommended continuation of its ongoing Phase II trial of CH-4051 in rheumatoid arthritis and that it should initiate enrollment in the 3-mg dose group. Ten patients have completed treatment in the 0.3-mg and 1-mg dose cohorts, with no negative safety signals found by the DSMB. For the remainder of the trial, patients will be randomized to 0.3 mg, 1 mg or 3 mg of CH-4051 daily, 3 mg CH-4051 daily with folate supplement, or methotrexate weekly with folate supplement for 12 weeks.